OraSure Technologies Appoints New Chief Financial Officer
04 May 2018 - 8:00PM
OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care
diagnostic tests and specimen collection devices, today announced
that Roberto Cuca has been appointed as the Company’s new Chief
Financial Officer, effective as of June 8, 2018. Mr. Cuca
will initially serve as Senior Advisor to the Company until his
appointment is effective. Mr. Cuca will succeed Ronald H.
Spair, who will retire from the Company on the same date.
Since September 2013, Mr. Cuca has served as
Senior Vice President and Chief Financial Officer of Trevena, Inc.,
a clinical stage biopharmaceutical company, where he led the
finance and investor relations functions and worked with senior
management to establish and execute overall corporate
strategy. Prior to his time at Trevena, Mr. Cuca held various
leadership positions in the finance organization of Endo Health
Solutions Inc., a pharmaceutical company. His most recent
position at Endo was Treasurer and Senior Vice President, Finance,
where he was responsible for capital raises and cash management,
mergers, acquisitions and licensing transactions, tax planning and
compliance, and risk management. Before that, Mr. Cuca was
Director, Corporate and Business Development at moksha8
Pharmaceuticals, Inc., an emerging markets-focused pharmaceutical
company, and an equity analyst covering U.S. pharmaceutical
companies at J.P. Morgan Chase & Co. Mr. Cuca received an
M.B.A. from the Wharton School of the University of Pennsylvania, a
J.D. from Cornell Law School, and an A.B. from Princeton
University. Mr. Cuca is also a CFA Charterholder.
“We are delighted to welcome Roberto as the
Company’s new Chief Financial Officer,” said Stephen S. Tang,
Ph.D., President and CEO of OraSure Technologies. “Roberto’s
strong mix of finance, investor relations and business development
experience, and particularly his most recent experience as CFO of a
publicly-traded life sciences company, makes him especially well
qualified to be OraSure’s next Chief Financial Officer. We
look forward to working with Roberto in his new role and are
confident he will be a strong contributor for many years to
come.”
“I am very excited to be joining OraSure at this
important point in the Company’s history,” said Mr. Cuca. “I
look forward to contributing to the corporate strategy and its
implementation in the coming years, building on the significant
accomplishments OraSure has achieved to date.”
About OraSure
Technologies
OraSure Technologies is a leader in the
development, manufacture and distribution of point of care
diagnostic and collection devices and other technologies designed
to detect or diagnose critical medical conditions. Its
first-to-market, innovative products include rapid tests for the
detection of antibodies to HIV and HCV on the OraQuick® platform,
oral fluid sample collection, stabilization and preparation
products for molecular diagnostic applications, and oral fluid
laboratory tests for detecting various drugs of abuse. OraSure's
portfolio of products is sold globally to various clinical
laboratories, hospitals, clinics, community-based organizations and
other public health organizations, research and academic
institutions, distributors, government agencies, physicians'
offices, commercial and industrial entities and consumers. The
Company's products enable healthcare providers to deliver critical
information to patients, empowering them to make decisions to
improve and protect their health. For more information on
OraSure Technologies, please visit www.orasure.com.
Company contact:
Shauna WhiteCorporate Marketing
Manager484-353-1575media@orasure.comwww.orasure.com
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jul 2023 to Jul 2024